ARTICLE | Clinical News
AP23573: Phase II data
February 13, 2006 8:00 AM UTC
Data from an open-label, U.S. Phase II trial in up to 200 patients showed that 40% of evaluable patients demonstrated anti-cancer activity as defined by hematologic improvement and partial response. ...